Are there any data regarding safety or efficacy of osimertinib and concurrent chemotherapy in patients with metastatic NSCLC harboring sensitizing EGFR mutation?

The OPAL study evaluated 1st line osimertinib combined with platinum pemetrexed in 67 patients with EGFR mutated NSCLC in Japan (Saito et al., EJC 2023). The combination yielded an objective response rate of 90.9% (95% confidence interval, 84.0–97.8), with median PFS of 31.0 months (95% CI, 26.8â€...